Skip to main content

Pre-eclampsia

6
Pipeline Programs
16
Companies
12
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 17 programs with unclassified modality

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Young BioPharma
Young BioPharmaMA - Lowell
1 program
1
Tdap Vaccine AdministrationPhase 4Vaccine1 trial
Active Trials
NCT04424693Unknown1,600Est. Dec 2024
Human BioSciences
Human BioSciencesWV - Martinsburg
3 programs
1
1
Aspirin 162 mgPhase 31 trial
nicotinamidePhase 21 trial
Multi-Omics for Maternal Health After PreeclampsiaN/A1 trial
Active Trials
NCT06340152Recruiting1,100Est. Dec 2028
NCT03419364Completed23Est. Aug 2021
NCT06408181Recruiting1,150Est. Jun 2029
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Anti-digoxin antibodyPhase 2
Evergreen Therapeutics
Evergreen TherapeuticsChina - Hong Kong
1 program
1
EG-101Phase 11 trial
Active Trials
NCT07327255Not Yet Recruiting24Est. Mar 2027
Sandoz
SandozAustria - Kundl
1 program
1
recombinant human relaxinPhase 1
DiaMedica Therapeutics
DiaMedica TherapeuticsMINNEAPOLIS, MN
1 program
DM199N/A1 trial
Active Trials
NCT06875141Withdrawn0Est. May 2025
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Home Sleep Test with Watch PAT-oneN/A1 trial
Active Trials
NCT06702475Not Yet Recruiting100Est. Dec 2026
Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
1 program
Labor InductionN/A1 trial
Active Trials
NCT05056467Unknown825Est. Dec 2024
Genome & Company
Genome & CompanyKorea - Suwon
1 program
Multi-Omics for Maternal Health After PreeclampsiaN/A
Gedeon Richter
Gedeon RichterHungary - Budapest
1 program
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)N/A
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)N/A1 trial
Active Trials
NCT07263490Recruiting462Est. Jun 2028
Sigrid Therapeutics
Sigrid TherapeuticsSweden - Stockholm
1 program
Pre-eclampsia screening programN/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Prediction of Preeclampsia by Comprehensive Markers.N/A1 trial
Active Trials
NCT03665623Completed11,741Est. Aug 2020
Thermo Fisher Scientific
1 program
historyN/A
Novartis
NovartisBASEL, Switzerland
1 program
recombinant human relaxinPHASE_11 trial
Active Trials
NCT00333307Suspended18
GSK
GSKLONDON, United Kingdom
1 program
Anti-digoxin antibodyPHASE_21 trial
Active Trials
NCT00158743Completed51Est. Dec 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Young BioPharmaTdap Vaccine Administration
Human BioSciencesAspirin 162 mg
Human BioSciencesnicotinamide
GSKAnti-digoxin antibody
Evergreen TherapeuticsEG-101
Novartisrecombinant human relaxin
DiaMedica TherapeuticsDM199
Colorado TherapeuticsHome Sleep Test with Watch PAT-one
Ferring PharmaceuticalsPRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)
Human BioSciencesMulti-Omics for Maternal Health After Preeclampsia
Angel PharmaceuticalsLabor Induction
UNION therapeuticsPrediction of Preeclampsia by Comprehensive Markers.

Clinical Trials (12)

Total enrollment: 17,094 patients across 12 trials

NCT04424693Young BioPharmaTdap Vaccine Administration

Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36

Start: Dec 2020Est. completion: Dec 20241,600 patients
Phase 4Unknown
NCT06408181Human BioSciencesAspirin 162 mg

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

Start: Jun 2024Est. completion: Jun 20291,150 patients
Phase 3Recruiting
NCT03419364Human BioSciencesnicotinamide

Study of Nicotinamide in Early Onset Preeclampsia

Start: Nov 2017Est. completion: Aug 202123 patients
Phase 2Completed
NCT00158743GSKAnti-digoxin antibody

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

Start: Feb 2004Est. completion: Dec 200751 patients
Phase 2Completed
NCT07327255Evergreen TherapeuticsEG-101

Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia

Start: Jun 2026Est. completion: Mar 202724 patients
Phase 1Not Yet Recruiting
NCT00333307Novartisrecombinant human relaxin

Evaluation of the Safety of Relaxin in Preeclampsia

Start: Oct 200618 patients
Phase 1Suspended
NCT06875141DiaMedica TherapeuticsDM199

DM199 for Pregnancy Complications

Start: May 2025Est. completion: May 20250
N/AWithdrawn
NCT06702475Colorado TherapeuticsHome Sleep Test with Watch PAT-one

Are There Sleep-related Factors That Contribute to an Increased Incidence of Pre-eclampsia at Altitude?

Start: Apr 2025Est. completion: Dec 2026100 patients
N/ANot Yet Recruiting
NCT07263490Ferring PharmaceuticalsPRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

Start: Oct 2024Est. completion: Jun 2028462 patients
N/ARecruiting
NCT06340152Human BioSciencesMulti-Omics for Maternal Health After Preeclampsia

Multi-Omics for Maternal Health After Preeclampsia

Start: Dec 2023Est. completion: Dec 20281,100 patients
N/ARecruiting
NCT05056467Angel PharmaceuticalsLabor Induction

Labor Induction in Preeclampsia High-risk Women

Start: Jan 2022Est. completion: Dec 2024825 patients
N/AUnknown
NCT03665623UNION therapeuticsPrediction of Preeclampsia by Comprehensive Markers.

Prediction of Preeclampsia by Comprehensive Markers.

Start: Dec 2017Est. completion: Aug 202011,741 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 17,094 patients
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.